Glen R Gabler, MD | |
29 W Coleys Cv, Elk Ridge, UT 84651-4574 | |
(801) 423-3782 | |
Not Available |
Full Name | Glen R Gabler |
---|---|
Gender | Male |
Speciality | Family Medicine |
Location | 29 W Coleys Cv, Elk Ridge, Utah |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1609074350 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Q00000X | Family Medicine | 313524-1205 (Utah) | Primary |
Mailing Address | Practice Location Address |
---|---|
Glen R Gabler, MD 29 W Coleys Cv, Elk Ridge, UT 84651-4574 Ph: (801) 423-3782 | Glen R Gabler, MD 29 W Coleys Cv, Elk Ridge, UT 84651-4574 Ph: (801) 423-3782 |
News Archive
On the sidelines of the International Monetary Fund and World Bank meetings in Tokyo on Thursday, Japan and South Korea each pledged an additional $30 million over three years for the Global Agriculture and Food Security Program (GAFSP), established in 2010 to help improve food security in low-income countries, Reuters reports.
Apotex Inc, a Canadian owned pharmaceutical company with headquarters in Toronto, launched today Apo-Atorvastatin, a generic version of 'Lipitor(R)' produced by Pfizer(R). This is the largest product to be genericized in Canadian history with approximate yearly sales of $1.2 billion. This last patent on Lipitor(R) will not expire until 2022. Apotex Inc. invented its own crystal form, thus overcoming the patents, 12 years ahead of time, which will result in close to $7 billion of cost-savings for the Canadian healthcare system.
The U.S. Department of Defense has awarded a team of scientists and physicians from leading health care institutions across Phoenix a $1.3 million grant over three years to study traumatic brain injury and its relationship to dementia.
Researchers have discovered a unique metabolic "signature" in the urine of diabetic, obese black teenagers that they say may become a way to predict the development of type 2 diabetes in people at risk.
Amgen today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion to extend the marketing authorization for Vectibix (panitumumab) to include combination with FOLFIRI (an irinotecan-based chemotherapy) as first-line treatment in adult patients with wild-type RAS metastatic colorectal cancer (mCRC).
› Verified 7 days ago
Dennis Michael Concoby, D.O. Family Medicine Medicare: Medicare Enrolled Practice Location: 107 W Goosenest Dr, Elk Ridge, UT 84651 Phone: 801-358-9954 |